Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by D.C. Malone
Pms38 - Cost Effectiveness Analysis of Secukinumab Versus Ustekinumab for the Treatment of Psoriatic Arthritis in the United States
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
PHP64 the Incidence of Potential Drug-Drug Interactions Originating From the Same Prescriber
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Related publications
Pmu67 - Cost-Effectiveness Analysis of Ixekizumab Versus Secukinumab in Patients With Psoriatic Arthritis and Concomitant Moderate-To-Severe Psoriasis in the United Kingdom
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Cost-Effectiveness Analysis of Endovascular Versus Neurosurgical Treatment for Ruptured Intracranial Aneurysms in the United States
Journal of Neurosurgery
Surgery
Neurology
Pmu66 - Cost-Effectiveness Analysis of Ixekizumab Versus Secukinumab in Patients With Psoriatic Arthritis and Concomitant Moderate-To-Severe Psoriasis in Spain
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pms28 - Secukinumab Versus Infliximab in the Treatment of Psoriatic Arthritis: A Cost Per Responder Analysis Among 48 Weeks From a Tunisian Perspective.
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pms27 - Secukinumab Versus Adalimumab in the Treatment of Psoriatic Arthritis: A Cost Per Responder Analysis Among 48 Weeks From a Tunisian Perspective.
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pms45 - Cost Per Responder Analysis Following a 48-Week Psoriatic Arthritis Treatment With Secukinumab Versus Adalimumab From the Portuguese Payer Perspective
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pss35 - Secukinumab Versus Ustekinumab for the Treatment of Psoriasis: A 52-Week Cost Per Responder Analysis From the Portuguese Payer Perspective
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Cost-Effectiveness Analysis Evaluating Fidaxomicin Versus Oral Vancomycin for the Treatment of Clostridium Difficile Infection in the United States
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Cost-Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccine in the United States
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
